# Boon Cher Goh

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/boon-cher-goh/

## Facts

| Field | Value |
| --- | --- |
| Citations | 17,713 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 67 |
| i10-index | 180 |
| Last Known Institution | National University of Singapore |
| OpenAlex ID | https://openalex.org/A5043184297 |
| ORCID iD | 0000-0002-4107-102X |
| Works | 465 |

## Researcher papers

- [Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study](https://scholariq.org/papers/pembrolizumab-alone-or-with-chemotherapy-versus-cetuximab-with-chemotherapy-for/)
- [Dual role of autophagy in hallmarks of cancer](https://scholariq.org/papers/dual-role-of-autophagy-in-hallmarks-of-cancer/)
- [Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs](https://scholariq.org/papers/mechanism-based-inhibition-of-cytochrome-p450-3a4-by-therapeutic-drugs/)
- [Exosome-Mediated Metastasis: From Epithelial–Mesenchymal Transition to Escape from Immunosurveillance](https://scholariq.org/papers/exosome-mediated-metastasis-from-epithelial-mesenchymal-transition-to-escape/)
- [Resveratrol for cancer therapy: Challenges and future perspectives](https://scholariq.org/papers/resveratrol-for-cancer-therapy-challenges-and-future-perspectives/)
- [Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)](https://scholariq.org/papers/antitumor-activity-of-nivolumab-in-recurrent-and-metastatic-nasopharyngeal/)
- [Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study](https://scholariq.org/papers/efficacy-of-pazopanib-in-progressive-radioiodine-refractory-metastatic/)
- [The genomic landscape of nasopharyngeal carcinoma](https://scholariq.org/papers/the-genomic-landscape-of-nasopharyngeal-carcinoma/)
- [Multicenter, Phase II Study of Cetuximab in Combination With Carboplatin in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma](https://scholariq.org/papers/multicenter-phase-ii-study-of-cetuximab-in-combination-with-carboplatin-in/)
- [Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer](https://scholariq.org/papers/functional-genomics-identifies-five-distinct-molecular-subtypes-with-clinical/)
- [Dynamics of multiple resistance mechanisms in plasma DNA during EGFR‐targeted therapies in non‐small cell lung cancer](https://scholariq.org/papers/dynamics-of-multiple-resistance-mechanisms-in-plasma-dna-during-egfr-targeted/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Head and Neck Cancer Studies](https://scholariq.org/topics/head-and-neck-cancer-studies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [National University of Singapore](https://scholariq.org/institutions/national-university-of-singapore/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.